Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics
The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Abstract
Human cells possess tightly controlled mechanisms to rescue DNA replication following DNA damage caused by environmental and endogenous carcinogens using a set of low-fidelity translesion synthesis (TLS) DNA polymerases. These polymerases can copy over replication blocking DNA lesions while temporarily leaving them unrepaired, preventing cell death at the expense of increasing mutation rates and contributing to the onset and progression of cancer. In addition, TLS has been implicated as a major cellular mechanism promoting acquired resistance to genotoxic chemotherapy. Owing to its central role in mutagenesis and cell survival after DNA damage, inhibition of the TLS pathway has emerged as a potential target for the development of anticancer agents. This review will recap our current understanding of the structure and regulation of DNA polymerase complexes that mediate TLS and describe how this knowledge is beginning to translate into the development of small molecule TLS inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TLS is considered a potential target in cancer therapy [98,108,109]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [109]
In the citing paper
“Because TLS events may protect tumor cells by favoring DNA replication”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [109]
Citations
Cites
Friedberg, E. C., Walker, G. C., Siede, W., Wood, R. D., Schultz, R. A., & Ellenberger, T. (2005) · doi:10.1128/9781555816704 · Cited by 5,683
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Structure and function of telomeres
Blackburn, E. H. (1991) · Nature · doi:10.1038/350569a0 · Cited by 3,596
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Hoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239
RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO
Hoege, C., Pfander, B., Moldovan, G.-L., Pyrowolakis, G., & Jentsch, S. (2002) · Nature · doi:10.1038/nature00991 · Cited by 2,198
A Hot Spot of Binding Energy in a Hormone-Receptor Interface
Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,983
PCNA, the Maestro of the Replication Fork
Moldovan, G.-L., Pfander, B., & Jentsch, S. (2007) · Cell · doi:10.1016/j.cell.2007.05.003 · Cited by 1,796
Cited by
Mechanisms of DNA damage, repair, and mutagenesis
Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039
Translesion DNA polymerases in eukaryotes: what makes them tick?
Vaisman, A., & Woodgate, R. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1291576 · Cited by 249
“A surge of interest in this topic is illustrated by the fact that it has been the focus of numerous recent review articles (Jansen et al., 2015; Knobel & Marti, 2011; Korzhnev & Hadden, 2016; Lange et al., 2011; Maga & Hubscher, 2008; Makridakis & Reichardt, 2012; Tomasso et al., 2014).”
BackgroundNayak, S. U., Calvo, J. A., Cong, K., Peng, M., Berthiaume, E. A., Jackson, J., Zaino, A. M., Vindigni, A., Hadden, M. K., & Cantor, S. B. (2020) · Science Advances · doi:10.1126/sciadv.aaz7808 · Cited by 120
Self-citationCDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication
Mansilla, S. F., De La Vega, M. B., Calzetta, N. L., Siri, S. O., & Gottifredi, V. (2020) · Genes · doi:10.3390/genes11060593 · Cited by 114
Maneuvers on PCNA Rings during DNA Replication and Repair
Slade, D. (2018) · Genes · doi:10.3390/genes9080416 · Cited by 100
“On the other hand, uncontrolled access of TLS polymerases to replication forks may enhance mutagenesis thus contributing to oncogenic transformation [186].”
BackgroundTranslesion Synthesis: Insights into the Selection and Switching of DNA Polymerases
Zhao, L., & Washington, M. T. (2017) · Genes · doi:10.3390/genes8010024 · Cited by 90
“In addition, TLS pols are over-expressed in a number of cancers, which is considered to be a contributing factor to mutagenicity and resistance to chemotherapies [25,43].”
BackgroundInfluentialSail, V., Rizzo, A. A., Chatterjee, N., Dash, R. C., Ozen, Z., Walker, G. C., Korzhnev, D. M., & Hadden, M. K. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01144 · Cited by 52
Self-citationPolymerase iota - an odd sibling among Y family polymerases
McIntyre, J. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102753 · Cited by 52
Translesion DNA Synthesis in Cancer: Molecular Mechanisms and Therapeutic Opportunities
Zafar, M. K., & Eoff, R. L. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00157 · Cited by 53
Translesion synthesis inhibitors as a new class of cancer chemotherapeutics
Patel, S. M., Dash, R. C., & Hadden, M. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1850692 · Cited by 41
Self-citationThe Rev1-Polζ translesion synthesis mutasome: Structure, interactions and inhibition
Rizzo, A. A., & Korzhnev, D. M. (2019) · The Enzymes · doi:10.1016/bs.enz.2019.07.001 · Cited by 42
“The Rev1-CT/Rev7 interface also contains druggable pockets (Figure 13B) [62], and a small molecule inhibitor Rizzo and Korzhnev Page 18”
BackgroundSelf-citationTargeting translesion synthesis (TLS) to expose replication gaps, a unique cancer vulnerability
Nayak, S. U., Calvo, J. A., & Cantor, S. B. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1864321 · Cited by 39
Structure and function relationships in mammalian DNA polymerases
Hoitsma, N. M., Whitaker, A. M., Schaich, M. A., Smith, M. R., Fairlamb, M. S., & Freudenthal, B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03368-y · Cited by 41
Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy
McPherson, K. S., & Korzhnev, D. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00101a · Cited by 39
Self-citationWang, X., Pernicone, N., Pertz, L., Hua, D., Zhang, T., Listovsky, T., & Xie, W. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010123 · Cited by 33
Stanzione, M., Zhong, J., Wong, E., LaSalle, T. J., Wise, J. F., Simoneau, A., Myers, D. T., Phat, S., Sade-Feldman, M., Lawrence, M. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn1229 · Cited by 33
“This hypothesis was further supported by a novel small-molecule inhibitor of TLS, TLSpp, which disrupts the interaction of REV1 with other TLS DNA polymerases (49, 50).”
BackgroundSelf-citationNon-bulky Lesions in Human DNA: The Ways of Formation, Repair, and Replication
Ignatov, А. V., Bondarenko, K. A., & Makarova, A. V. (2017) · Acta Naturae · doi:10.32607/20758251-2017-9-3-12-26 · Cited by 31
Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2
Wang, Y., Zhou, X., Wu, Z., Hu, H., Jin, J., Hu, Y., Dong, Y., Zou, J., Mao, Z., Shi, X., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.170 · Cited by 30
Geronimo, I. M., Vidossich, P., Donati, E., & Vivo, M. D. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1534 · Cited by 27
“17,18 Additionally, these DNA Pols can decrease the efficacy of chemotherapy by bypassing the nucleotide adducts formed by anticancer agents.”
BackgroundWilson, K. A., Fernandes, P. A., Ramos, M. J., & Wetmore, S. D. (2019) · ACS Catalysis · doi:10.1021/acscatal.8b04889 · Cited by 23
The dark side of the ring: role of the DNA sliding surface of PCNA
March, M. D., & Biasio, A. D. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1364218 · Cited by 23
Gowda, A. S. P., Lee, M., & Spratt, T. E. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611607 · Cited by 23
Molecular Docking Analysis of Caspase-3 Activators as Potential Anticancer Agents
Kashaw, S. K., Agarwal, S., Mishra, M., Sau, S., & Iyer, A. K. (2018) · Current Computer - Aided Drug Design · doi:10.2174/1573409914666181015150731 · Cited by 20
Fork Protection and Therapy Resistance in Hereditary Breast Cancer
Cantor, S. B., & Calvo, J. A. (2017) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2017.82.034413 · Cited by 22
“Importantly, significant progress has been made in the development of TLS inhibitors (Actis et al. 2013; Korzhnev and Hadden 2016; Cold Spring Harb Symp Quant Biol.”
BackgroundIveland, T. S., Hagen, L., Sharma, A., de Sousa, M. M. L., Sarno, A., Wollen, K. L., Liabakk, N., & Slupphaug, G. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02318-8 · Cited by 19
Geronimo, I. M., Vidossich, P., & Vivo, M. D. (2021) · ACS Catalysis · doi:10.1021/acscatal.1c03840 · Cited by 16
Dash, R. C., Ozen, Z., McCarthy, K. R., Chatterjee, N., Harris, C. A., Rizzo, A. A., Walker, G. C., Korzhnev, D. M., & Hadden, M. K. (2019) · ChemMedChem · doi:10.1002/cmdc.201900307 · Cited by 15
Self-citationTargeting proliferating cell nuclear antigen (PCNA) for cancer therapy
Søgaard, C. K., & Otterlei, M. (2024) · Advances in pharmacology · doi:10.1016/bs.apha.2024.04.002 · Cited by 16
Fenteany, G., Gaur, P., Hegedűs, L., Dudás, K., Kiss, E., Wéber, E., Hackler, L., Martinek, T. A., Puskás, L. G., & Haracska, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-48888-6 · Cited by 14
Touny, L. H. E., Hose, C. D., Connelly, J., Harris, E. D., Monks, A. P., Dull, A. B., Wilsker, D. F., Hollingshead, M. G., Gottholm-Ahalt, M. M., Alcoser, S. Y., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.28090 · Cited by 12
“Low-fidelity polymerases, such as Pol ζ, Pol κ, Pol ι, Pol η, and REV1, are key players in TLS and several reports indicate that their overexpression enhances DDR, resulting in resistance to DNA damaging therapy [15].”
The importance of an interaction network for proper DNA polymerase ζ heterotetramer activity
Szwajczak, E., Fijałkowska, I. J., & Suski, C. (2017) · Current Genetics · doi:10.1007/s00294-017-0789-1 · Cited by 11
“2015; Korzhnev and Hadden 2016; Vaisman and Woodgate 2017; Zhao and Washington 2017).”
BackgroundProtein Assemblies in Translesion Synthesis
Arianna, G. A., & Korzhnev, D. M. (2024) · Genes · doi:10.3390/genes15070832 · Cited by 12
“…than the replicative polymerases, and (iii) are more prone to incorrect base pairing due to the lack of 3′-5′ exonuclease activity [23,42]. from [32]. adapted to accommodate DNA lesions, (ii) form overall fewer contacts with primer/template p/t) DNA than the replicative polymerases, and (iii)…”
BackgroundInfluentialSelf-citationLatância, M. T., Leandro, G. D. S., Bastos, A. U., Moreno, N. C., Ariwoola, A.-B. A., Martins, D. J., Ashton, N. W., Ribeiro, V. C., Hoch, N. C., Rocha, C. R. R., et al. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103715 · Cited by 12
Robust high-throughput assays to assess discrete steps in ubiquitination and related cascades
Fenteany, G., Gaur, P., Sharma, G., Pintér, L., Kiss, E., & Haracska, L. (2020) · BMC Molecular and Cell Biology · doi:10.1186/s12860-020-00262-5 · Cited by 9
Cranford, M. T., Kaszubowski, J. D., & Trakselis, M. A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa803 · Cited by 9
McPherson, K. S., Zaino, A. M., Dash, R. C., Rizzo, A. A., Li, Y., Hao, B., Bezsonova, I., Hadden, M. K., & Korzhnev, D. M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000893 · Cited by 9
Self-citationMunafò, F., Nigro, M., Brindani, N., Manigrasso, J., Geronimo, I. M., Ottonello, G., Armirotti, A., & Vivo, M. D. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115044 · Cited by 8
Averill, J. R., & Jung, H. (2023) · Biochemical Journal · doi:10.1042/bcj20230029 · Cited by 7
Degtyareva, N. P., Placentra, V. C., Gabel, S. A., Klimczak, L. J., Gordenin, D. A., Wagner, B. A., Buettner, G. R., Mueller, G. A., Smirnova, T. I., & Doetsch, P. W. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad305 · Cited by 6
Human TLS DNA polymerase: saviors or threats under replication stress?
Rajpurohit, Y. S., Lal, M., Sharma, D. K., & Soni, I. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05291-2 · Cited by 6
Fujii, N. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00358 · Cited by 7
A stapled POL κ peptide targets REV1 to inhibit mutagenic translesion synthesis
Chatterjee, N., D’Souza, S., Mir, M. S., Harris, C. A., Hilinski, G. J., Verdine, G. L., & Walker, G. C. (2020) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22395 · Cited by 5
“It seems most likely that the effect is due to the stapled POL κ RIR peptide preventing both the RIR containing polymerases, including POLD3, a component of POL ζ4, from interacting with the RIR interface of the Rev1 CTD.”
BackgroundInfluentialJamwal, R. S., Mahajan, N., Bhat, G. R., Bhat, A., Sharma, B., Shah, R., Sharma, M., Verma, S., Bakshi, D., Sharma, R., et al. (2021) · Cancer Epidemiology · doi:10.1016/j.canep.2021.102047 · Cited by 6
Calzetta, N. L., Mansilla, S. F., Ahlers, C. M., Bertolin, A. P., Caimi, L. I., Arbilla, S. V., Zeng, J., Wiesmüller, L., & Gottifredi, V. (2025) · Science Advances · doi:10.1126/sciadv.adw4618 · Cited by 6
Khodaverdian, V. Y., Sano, T., Maggs, L. R., Tomarchio, G., Dias, A., Clairmont, C., Tran, M., & McVey, M. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011181 · Cited by 3
Zaino, A. M., Dash, R. C., James, S. J., MacGilvary, N. J., Crompton, A., McPherson, K. S., Stanzione, M., Korzhnev, D. M., Dyson, N. J., Chatterjee, N., et al. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117755 · Cited by 3
Self-citationZhang, Q., & Tretyakova, N. Y. (2023) · Biochemical Journal · doi:10.1042/bcj20230159 · Cited by 2
REV1 inhibition enhances trinucleotide repeat mutagenesis
Siegel, A., Almstead, D., Kothandaraman, N., Reich, J., Lamkin, E. N., Victor, J., Grover, A., Ikeh, K., Koval, H., Crompton, A., et al. (2025) · Open Biology · doi:10.1098/rsob.250234 · Cited by 2
Self-citationGowda, A. S. P., Lee, M., & Spratt, T. E. (2017) · Angewandte Chemie · doi:10.1002/ange.201611607 · Cited by 2
Chechik, L. L. (2020) · theses.fr (ABES) · doi:10.70675/7a0f8e0bzfd35z44dbzaf70z67d381d06b41
Jamwal, R. S., Mahajan, N., Bhat, G. R., Bhat, A., Sharma, B., Shah, R., Sharma, M., Verma, S., Bakshi, D., Sharma, R., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-42137/v2
Probing hot spots of protein-protein interactions mediated by the safety-belt region of REV7
Dash, R. C., Arianna, G. A., Patel, S. M., Rizzo, A. A., Harrahill, N. J., Korzhnev, D. M., & Hadden, M. K. (2024) · Structure · doi:10.1016/j.str.2024.09.007 · Cited by 1
Self-citationIveland, T. S., Hagen, L., Sharma, A., Sousa, M. M. L., Sarno, A., Wollen, K. L., Liabakk, N. B., & Slupphaug, G. (2020) · Figshare · doi:10.6084/m9.figshare.12097560
PCNA-Polκ-Polδ/USP18 axes stabilize replication fork and restart to reduce cisplatin cytotoxicityPreprint
Subhadarsini, I., Sahu, J. K., Thakur, S., Dash, R., & Acharya, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.08.730955
“Although Pol and Pol are involved in cisplatin resistance, suitable inhibitors against these polymerases are yet to be identified and validated as chemotherapeutics (Korzhnev and Hadden 2016; Patel et al. 2021).”
PCNA-Polκ-Polδ/USP18 axes stabilize replication fork and restart to reduce cisplatin cytotoxicityPreprint
Subhadarsini, I., Sahu, J. K., Thakur, S., Dash, R., & Acharya, N. (2026) · eLife · doi:10.7554/elife.112155.1
Subhadarsini, I., Sahu, J. K., Thakur, S., Dash, R., & Acharya, N. (2026) · eLife · doi:10.7554/elife.112155.1.sa0
PCNA-Polκ-Polδ/USP18 axes stabilize replication fork and restart to reduce cisplatin cytotoxicityPreprint
Subhadarsini, I., Sahu, J. K., Thakur, S., Dash, R., & Acharya, N. (2026) · eLife · doi:10.7554/elife.112155
Niedermayer, K., Greco, S., Oechsle, A., Köhler, T., Pantel, K., Friedl, T. W. P., Janni, W., Rack, B., Pfister, K., Gottifredi, V., et al. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03377-4
“Recent strategies aim at inhibitors of fork remodeling or repriming [7, 23, 24], but overall, the TLS pathway has been the primary focus [25 – 27].”
Metadata
- Authors
- Korzhnev, D. M., & Hadden, M. K.
- Affiliations
- UConn Health (US)
- University of Connecticut (US)
- Corresponding author
- Korzhnev, Dmitry M.
- Hadden, M. Kyle
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-07-19
- Volume
- 59
- Issue
- 20
- Pages
- 9321-9336
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2466355266
- Cited by
- 58
- References
- 181
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 7 · 2023: 4 · 2022: 1 · 2021: 6 · 2020: 10 · 2019: 7 · 2018: 3 · 2017: 12
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA190617)
- Division of Molecular and Cellular Biosciences (1515808)
- American Cancer Society (RSG-13-131-01)
- University of Connecticut Health Center
- University of Connecticut Research Foundation
- Connecticut Institute for Clinical and Translational Science, University of Connecticut
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- translesion synthesis, DNA polymerase, DNA damage, mutagenesis, chemoresistance, DNA replication, small molecule inhibitors
- MeSH terms
- Animals, Antineoplastic Agents, Cell Survival, DNA Damage, DNA-Directed DNA Polymerase, Dose-Response Relationship, Drug, Humans, Neoplasms, Structure-Activity Relationship, Molecular Structure, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.